SCHEMBL13387250

SCHEMBL13387250

CCN1C[C@@H](NC(=O)c2nc3c(s2)CN(C)CC3)[C@H](NC(=O)c2cc3cc(Cl)ccc3[nH]2)C1=O

nearest known ligand 0.75

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 20/20 0.75
▸ F2 P00734 4/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14224851 0.93 F10 (0.75) F10F2
Hydrochloric Acid SCHEMBL2939795 0.92 F10 (0.74) F10F2
Hydrochloric Acid SCHEMBL2939793 0.92 F10 (0.74) F10F2
SCHEMBL1253905 0.92 F10 (0.81) F10F2
SCHEMBL1253647 0.91 F10 (0.71) F10F2
SCHEMBL1253648 0.91 F10 (0.71) F10F2
Hydrochloric Acid SCHEMBL1503989 0.91 F10 (0.70) F10F2
SCHEMBL2186825 0.88 F10 (0.70) F10F2
SCHEMBL2186829 0.88 F10 (0.70) F10F2
SCHEMBL13631342 0.88 F10 (0.82) F10F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093785-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2010-04-15 — — US disclosed
US-20090281074-A1 DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM DAIICHI PHARMACEUTICAL CO., LTD (JP) 2009-11-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093785-A1 DIAMINE DERIVATIVES C9, C1S, C1R F10 72/4885F2 4/4885
US-20090281074-A1 DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM C1R, C9, F2 F10 127/4885F2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback